Home » USA Broker Ratings » Gilead Sciences – Consenus Indicates Potential 16.6% Upside

Gilead Sciences – Consenus Indicates Potential 16.6% Upside

Gilead Sciences with ticker code (GILD) now have 24 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 95 and 60 with the average target price sitting at 78.29. Given that the stocks previous close was at 67.15 this would indicate that there is a potential upside of 16.6%. The day 50 moving average is 65.43 while the 200 day moving average is 65.33. The company has a market cap of $85,562m. Visit the company website at: http://www.gilead.com

Gilead Sciences, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company’s products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco ; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer; Sangamo Therapeutics; Gadeta B.V.; HiFiBiO Therapeutics; Agenus ; HOOKIPA Pharma ; Goldfinch Bio; insitro ; Nurix Therapeutics; Lyndra Therapeutics; Carna Biosciences ; and Glympse Bio, as well as the Chengdu Hi-tech Zone. The company was founded in 1987 and is headquartered in Foster City, California.

Join us on our new LinkedIn page

Follow us on LinkedIn